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Abstract
Fibrosis, characterized by excessive extracellular matrix accumu-
lation, is a common feature of many connective tissue diseases,
notably scleroderma (systemic sclerosis). Experimental studies
suggest that a complex network of intercellular interactions
involving endothelial cells, epithelial cells, fibroblasts and immune
cells, using an array of molecular mediators, drives the pathogenic
events that lead to fibrosis. Transforming growth factor-β and
endothelin-1, which are part of a cytokine hierarchy with connec-
tive tissue growth factor, are key mediators of fibrogenesis and are
primarily responsible for the differentiation of fibroblasts toward a
myofibroblast phenotype. The tight skin mouse (Tsk-1) model of
cutaneous fibrosis suggests that numerous other genes may also
be important.
Introduction
Fibrosis, the result of excess synthesis and deposition of
collagen, is a feature of many connective tissue diseases
(CTDs) and is the hallmark of scleroderma (systemic
sclerosis [SSc]). In this rare, progressive and life-threatening
autoimmune disease, fibrosis affects not only the skin but
also internal organs such as lungs and kidneys, leading to
organ dysfunction and failure [1]. In SSc, fibrosis is the final
stage in a series of pathological events that begins with
vascular dysfunction, manifesting as altered vascular tone,
endothelial activation and oxidative stress, followed by
immunological activation and leucocyte-mediated extra-
vascular inflammation [2]. A complex network of intercellular
interactions that involves a diverse range of molecules,
including growth factors, cytokines, chemokines and
endothelin, is believed to drive the pathological events that
ultimately result in uncontrolled connective tissue fibrosis. In
this review, which describes results from in vitro systems and
animal models of cutaneous and visceral fibrosis, we explore
cellular and molecular events associated with the initiation
and maintenance of fibrosis in CTDs.
Initiators of fibrosis in connective tissue
diseases
Fibrosis arises from excessive collagen synthesis by
fibroblasts [3]. Of the many potential mediators of fibrosis in
CTDs, three molecular entities appear to be of particular
importance: transforming growth factor (TGF)-β, endothelin
(ET)-1 and connective tissue growth factor (CTGF/CCN2). In
connective tissues, endothelin participates in stimulating the
formation of myofibroblasts (the myofibroblast is a specialized
type of fibroblast that is a normal cellular constituent of
healing tissues) and increases levels of CTGF and matrix
proteins [4] (Figure 1). It also interacts with other profibrotic
cytokines including TGF-β, which is a key component in the
induction and progression of fibrosis [5] and is a potent
stimulator of CTGF. Indeed, CTGF is a common target for
both TGF-β and ET-1.
Data from experimental animal studies have shed light on the
relationship between these three key mediators of fibrosis
and pointed to the existence of a cytokine hierarchy. This
hierarchy involves induction of ET-1 by TGF-β, induction of
CTGF by both ET-1 and TGF-β, and potential mediation of
the effects of TGF-β and ET-1 on extracellular matrix (ECM)
by CTGF [6] (Figure 2).
Evidence that TGF-β increases ET-1 mRNA expression has
come from several studies including an RNase protection
assay, in which bovine endothelial cells were incubated in the
presence or absence TGF-β and ET-1 mRNA expression was
measured over time. In cells exposed to TGF-β there was a
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marked, dose-dependent increase in ET-1 mRNA expression,
peaking at 4 hours after exposure [7]. Moreover, recent
studies have also shown that TGF-β can induce ET-1
production by pulmonary fibroblasts via a Smad-independent
signalling pathway involving c-Jun amino-terminal kinase and
the transcription factor activator protein-1. This pathway was
found to be constitutively activated in injured cells [8].
Results from in vivo studies suggest that the effect of TGF-β
on ET-1 production occurs primarily in response to cell injury.
In injured cells taken from bile duct ligated animals and
exposed to TGF-β, there was a notable increase in ET-1
production in the injured stellate cells but not in injured
endothelial cells (Figure 3a) [9].
These findings suggest that induction of ET-1 by TGF-β
requires an activation step, perhaps dependent on inflam-
matory status or other cellular signals. Interestingly, blocking
the effects of TGF-β with a soluble TGF-β receptor (STR)
antagonist leads to inhibition of ET-1 production by both
injured stellate and normal endothelial cells in vivo
(Figure 3b) [9]. The concept of a cytokine hierarchy, in which
ET-1 is induced by TGF-β, is also supported by data from
experimental studies that showed that ET-1 does not
increase TGF-β gene expression or increase TGF-β protein
production in vascular smooth muscle cells [10].
As mentioned above, CTGF is a common target for both
TGF-β and ET-1. Recent studies showed that ET-1 regulates
CTGF independently of TGF-β and that, in turn, CTGF
mediates ET-1 induced ECM accumulation. In an experi-
mental study in which vascular smooth muscle cells were
treated with 8 to 10 mol/l ET-1, there was a marked increase
Figure 1
Effects of endothelin include stimulating myofibroblast formation, leading to a concomitant increase in collagen production and fibrosis. Binding of
endothelin (ET)-1 to ET-1 receptor subtype A (ETA) and ETB has different effects in different cell types. The binding of ET-1 to smooth muscle cell
ETA and ETB receptors leads to vasoconstriction and mitogenesis, and activation of ETB receptors on endothelial cells promotes the release of
nitric oxide and prostacyclin, and plays a minor role in endothelial dependent vasodilatation. In fibroblasts ET-1 results in the increased production
of collagen and leads to fibrosis. Reproduced with permission from Galiè et al. Cardiovascular Research © Elsevier 2004 [4].
Figure 2
Schematic diagram of the hierarchy and interplay between ET-1,
TGF-β and CTGF. CTGF, connective tissue growth factor; 
ET, endothelin; NF-κB, nuclear factor-κB; TGF, transforming growth
factor. Reproduced from [6] by permission of the publisher 
(Taylor & Francis Ltd, http://www.informaworld.com).
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in type 1 collagen expression compared with control cells.
However, when the treated cells were exposed to a CTGF
antisense oligonucleotide that blocks the action of CTGF,
type 1 collagen expression was markedly suppressed. Similar
results were reported for levels of fibronectin, the production
of which is also influenced by both ET-1 and CTGF [10].
From the available evidence it seems clear that TGF-β can
induce ET-1, although its induction is variable and may be
dependent on other signals such as inflammation. Both
TGF-β and ET-1 can induce CTGF, with ET-1 acting indepen-
dently of TGF-β. CTGF, a cytokine that stimulates fibroblast
growth and upregulation of collagen and fibronectin in vitro
[11], is a difficult molecule to study experimentally, but there
is evidence to suggest it mediates certain effects of TGF-β
and ET-1 on ECM production [12,13]. More complex inter-
actions between TGF-β and ET-1 are likely to depend on
cross-regulation of receptors and activators.
Models of the profibrotic microenvironment
Models of organ fibrosis
The in vivo effects of ET-1 on cardiac, renal and pulmonary
tissue have been studied in a number of animal models of
fibrosis. Experimental work on salt-induced hypertension in
rodents (deoxycorticosterone acetate-salt hypertensive rats),
for example, found a marked increase in fibrosis in the
myocardium of affected animals compared with controls.
However, when animals were given treatment with a selective
endothelin-1 receptor subtype A antagonist, effective endo-
thelin blockade resulted in no collagen deposition in cardiac
tissue [14]. Earlier work on ET-1 transgenic mice, created by
the transfer of the human ET-1 gene locus into the germline
of mice, resulted in a pathological phenotype characterized
by glomerulosclerosis, interstitial fibrosis and renal cysts
without hypertension. In this model, pronounced renal fibrosis
was associated with an age-dependent decrease in
glomerular filtration that culminated in fatal kidney disease
[15]. The severe ET-1-induced renal disease seen in this
model of fibrosis is consistent with evidence from patients
that an activated renal endothelin system is associated with
glomerular and interstitial injury [15]. Other work in a
transgenic mouse model has shown ET-1 over-expression to
lead to the recruitment of inflammatory cells in respiratory
tissues and subsequent development of progressive
pulmonary fibrosis [16].
Models of skin fibrosis
More recently, a tight-skin mouse (Tsk-1) model has been
used to enhance understanding of the underlying pathology
of skin fibrosis in SSc. Tsk-1 mice develop tightening of the
skin to the underlying tissues, due to a mutation in the gene
encoding fibrillin 1. Fibrillin is a large ECM structural protein
and the major component of microfibrils, found with or
without associated elastin [17]. The primary role of fibrillin is
to form the scaffolding for elastic fibres. In Tsk-1 mice, fibrillin
appears to alter fibrillin matrix structure, with a notable
increase in fibrillin in the superficial fascia of these animals.
Tsk-1 mice exhibit increased elastogenesis in the superficial
fascia (gain-of-function) and a loss of the dense elastic fibre
band normally found at the interface between the intradermal
muscle and deep connective tissue (loss-of-function).
To test the hypothesis that Tsk fibrillin causes skin tethering
and fibrosis by altering interactions between fibrillin-1 and
other proteins, we conducted a series of experiments
focusing in particular on microfibril-associated glycoprotein
(MAGP)-1 and MAGP-2, fibulins, versican, decorin (small
Available online http://arthritis-research.com/content/9/S2/S4
Figure 3
TGF-β plays a pivotal role in the induction of ET-1. (a) Stellate (top
panel) and sinusoidal endothelial (bottom panel) cells were isolated from
normal rat livers or those injured by bile duct ligation (BDL). Transforming
growth factor (TGF)-β1 was applied at the indicated concentration in
serum-free medium for 24 hours. Endothelin (ET)-1 was measured by
radioimmunoassay. *P < 0.05 versus no TGF-β1 (n = 5). (b) Stellate and
endothelial cells were isolated from normal rat livers, and those after BDL
and those after soluble TGF-β1 receptor (STR) antagonist during BDL
(BDL + STR). *P < 0.05 versus normal and *P < 0.05 versus BDL
(n = 8). Reproduced with permission from Shao et al. Mol Biol Cell
2003 © The American Society for Cell Biology [9].
leucine-rich repeat proteoglycans) and latent TGF-β binding
proteins, all of which are proteins known to interact or co-
localize with fibrillin. Our results showed that MAGP-2 is
upregulated in Tsk-1 skin and in cells expressing Tsk fibrillin,
with the greatest increase seen in the hypodermis/superficial
fascia of Tsk skin (Figure 4a) [18]. Tsk-1 mice also lose
fibulin-5 expression at the interface between muscle and
superficial fascia; fibulin-5 is important in regulating elasto-
genesis (Figure 4b). Fibulin-2, a molecule related to fibulin-5,
was found to bind to both fibrillin and tropoelastin, and to be
present in increased amounts in the superficial fascia
(Figure 4c) [19]. Overall, these findings suggest that Tsk
fibrillin alters the binding of fibrillin to other matrix proteins
and that this altered binding appears to stimulate increased
MAGP-2 and fibulin-2 matrix. Increased MAGP-2 or fibulin-2
may in turn, directly or indirectly, stimulate collagen and
elastic fibre deposition leading to skin tethering. However,
MAGP-2 and fibulin-2 mRNA is also upregulated in Tsk skin,
raising the question of how matrix regulates matrix at the
mRNA level. There is evidence that Tsk fibrillin-1 alters TGF-β
activity in Tsk skin as well as altering the binding of fibrillin to
latent TGF-β binding proteins. Interestingly, TGF-β deleted
heterozygotes exhibit less fibrosis than do littermate Tsk
mice. Furthermore, studies using a hammerhead ribozyme to
specifically silence the mutant fibrillin in skin fibroblasts
derived from Tsk dermal biopsies revealed a striking
decrease in the expression of TGF-β dependent genes,
including that encoding CTGF, in Tsk skin cells where the
mutant fibrillin-1 had been deleted [20]. Ongoing studies in
which global changes in gene expression in Tsk-1 mice are
being assessed show that a variety of other proteins, in
addition to those mentioned above, may be of importance in
this model of skin fibrosis.
The Tsk-1 mouse clearly provides a good model for evalua-
ting how matrix regulates its own composition. Although there
is evidence from this model to suggest that Tsk fibrillin
regulates gene expression through altered interactions with
other matrix proteins, the identities of these mediators remain
to be elucidated.
A further model is the bleomycin-induced model of dermal
fibrosis, in which bleomycin has been found to increase
expression of ECM proteins, potentially via the mediation of
Arthritis Research & Therapy    Vol 9 Suppl 2 Krieg et al.
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Figure 4
The Tsk-1 model of cutaneous fibrosis exhibits increased MAGP-2, loss of fibulin-5 and increased fibulin-2 matrix. (a) Tissue sections from tight
skin (Tsk) mice (panels 1 and 3) and control (panels 2 and 4) mice were immunostained for microfibril-associated glycoprotein (MAGP)-2. MAGP-2
is indicated by arrowheads. MAGP-2 was detected at higher levels in all dermal layers (panel 1 versus panel 2). Hypodermis (H) is shown (panel 3
versus panel 4). PC, panniculus carnosus; D, dermis. (b) Control (left panel) and Tsk (right panel) mice skin sections from 6-week-old mice were
stained in parallel for fibulin-5 by immunohistochemistry. Positive staining is indicated by arrows at the muscle-connective tissue (M-CT) interface.
Hypodermal connective tissue (HD) and hypodermal muscle (M) are indicated. Original magnification: 400×. (c) Control (panels 1 and 3) and Tsk
(panels 2 and 4) mouse skin sections from 6-week-old mice were stained in parallel for fibulin-2 by immunohistochemistry. Positive staining is
indicated by arrows (M-CT interface) and in panel 4 around hair follicles (F). (a) Reproduced with permission from Lemaire et al. Arthritis Rheum
2004 © John Wiley & Sons/American College of Rheumatology [18]. (b) and (c) Reproduced with permission from [19].
TGF-β and CTGF/CCN2 [21]. This model has been widely
used to evaluate potential antifibrotic drugs. For example,
using this model, the protein kinase inhibitor imatinib mesylate
(a selective, dual inhibitor of TGF-β and platelet-derived
growth factor) was shown to have potent antifibrotic effects
[22], although perhaps not in later stages of fibrosis [23].
Peptide inhibitors of TGF-β1 applied topically are also
showing some promise [24]. Other agents targeting other
components of the fibrotic process have similarly demon-
strated attenuation of bleomycin-induced skin sclerosis in
mice [25].
Fibroblast to myofibroblast differentiation
In comparison with normal skin, biopsies of skin from SSc
patients show a significant increase in myofibroblasts,
particularly in the deep dermis. These cells, which are
characterized by the presence of stress fibres containing α-
smooth muscle actin (SMA), play a pivotal role in ECM
deposition and wound contraction during the normal wound
healing process [26]. A strong correlation has also been
observed between myofibroblast intensity in the skin of SSc
patients and the Rodnan skin score, which reflects disease
throughout the body. Thus, cutaneous changes in SSc
patients may reflect what is happening systemically, even
though the disease may not be clinically evident in large parts
of the body.
There has been much speculation on the origin of activated
fibroblasts in the skin of SSc patients and what influences
their differentiation toward a myofibroblast phenotype. There
is evidence that activated fibroblasts may arise from local
conversion of dermal fibroblasts by soluble factors, a finding
that is consistent with our CTGF staining data. It is also
possible that activated fibroblasts are recruited from
circulating or resting mesenchymal precursor cells in the
tissue, or induced by cell-cell contacts, cytokines or other
chemokines, or selected as an active subpopulation by one or
other mechanism. Alternatively, they may be generated by
clonal selection. As is discussed in greater detail below, in
wound healing the differentiation of fibroblasts toward a
myofibroblast phenotype is governed by several factors,
including the proximity of fibroblasts to keratinocytes, the
presence of endogenous TGF-β, and direct cell-cell contact
between fibroblasts and keratinocytes to allow initial TGF-β
activation.
Orchestrating fibrosis: interactions between
endothelial and other cells
In the initial stages of any fibrotic condition, and certainly in
SSc, there appears to be significant crosstalk between
different cell types, including endothelial and mesenchymal
cells. In vitro studies carried out during different stages of
wound healing have shed light on the general activation
mechanisms that are involved in fibrosis and on the
intercellular crosstalk that influences cell behaviour. In the
very early stages of wound healing, fibroblast activation is
induced by epithelial cells in response to injury. In the skin,
regulation during this very early phase of wound healing is
due to direct contact between keratinocytes and the
underlying fibroblasts, or to the release of cytokines from one
cell to another, or, indeed, a combination of both. Interaction
of fibroblasts and keratinocytes has also been found to
modulate levels of two key enzymes that are involved in
wound healing and remodelling: matrix metalloproteinase-2
and -9 [27]. This interaction may be critical for optimal
healing quality at a later stage in the wound healing process.
There is, in addition, close interplay and crosstalk between
the cells that control activation and downregulation of both
cell types. Thus, fibroblasts are known to release keratinocyte
growth factor, which induces keratinocytes to proliferate.
Importantly, it also acts as a switch, turning on the production
of other growth factors such as vascular endothelial growth
factor, which then signal to endothelial cells [28,29]. In a
recent series of experiments that included the incubation of
normal keratinocytes with fibroblasts in vitro, it was shown
that keratinocytes, either directly or indirectly, induced α-SMA
expression in fibroblasts [30]. Subsequently, it was dis-
covered that induction of α-SMA was associated with
induction of collagen RNA; myofibroblasts induced by
keratinocytes were found to produce large amounts of
collagen. For induction to take place, however, the keratino-
cytes and fibroblasts had to be in very close contact. The
genes induced as a result of the interaction between
keratinocytes and fibroblasts included ECM genes such as
collagens, tenascin C, decorin, transglutaminase and lysyl-
hydroxylase; cytoskeleton genes such as α-SMA; and cell-
cell signalling genes such as monocyte chemoattractant
protein 1, CTGF, activin A, ET-1 and angiopoietin (Table 1).
Angiopoietin-related growth factor can potently promote
adhesion, spreading and migration of keratinocytes,
fibroblasts and endothelial cells, with the adhesion and
migration events likely to be mediated by αv containing
integrins [31]. It has been suggested that α2β1 integrins are
responsible for cell attachment, spreading and migration.
However, a recent study [32] showed that although the α2β1
integrin is absolutely required for keratinocyte adhesion to
collagens, for fibroblasts other collagen-binding integrins may
partially make up for the lack of α2β1 in simple adhesion to
collagen monomers.
As later experiments have demonstrated, TGF-β is
responsible, at least in part, for the induction of α-SMA in
fibroblasts. Other important molecules involved in the regula-
tion of myofibroblast differentiation included the cytokine
granulocyte macrophage-colony stimulating factor, which
inhibited myofibroblast differentiation via induction of the
nuclear factor-κB pathway [33], and ET-1. In common with
TGF-β, ET-1 was also shown to induce α-SMA. However, it
appears to act synergistically with TGF-β to induce the myo-
fibroblast phenotype rather than acting alone (Figure 5).
Although there is evidence that additional factors are
Available online http://arthritis-research.com/content/9/S2/S4
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involved, the data suggest that ET-1 and TGF-β are
responsible for most of the induction of α-SMA-positive cells.
In cell culture experiments in which an anti-TGF-β antibody
and inhibitor of ET-1 were added to the co-culture, there was
significant downregulation of α-SMA activity. Moreover, a
recent study has shown TGF-β preferentially induces ET-1
expression [34].
Results from these experimental studies indicate that highly
complex epithelial-mesenchymal crosstalk is involved in
controlling the extent to which fibroblastic cells are induced in
the underlying mesenchyma and in their subsequent
differentiation to myofibroblasts.
Conclusion
As the experimental studies described here illustrate,
myofibroblasts play a central role in mediating tissue fibrosis,
which is the major clinical manifestation of CTDs such as
SSc. TGF-β, ET-1, and CTGF are among the most important
molecular mediators of fibrogenesis, with TGF-β and ET-1
intimately involved in the differentiation of fibroblasts toward a
myofibroblast phenotype, characterized by the presence of
stress fibres containing α-SMA. Cell culture experiments
show that direct cell-cell contact between fibroblasts and
keratinocytes is important for TGF-β activation and initiation
of myofibroblast formation. Data from animal models of
cardiac, renal, pulmonary and cutaneous fibrosis confirm the
importance of these profibrotic mediators in fibrogenesis,
while also highlighting other molecular entities that may be
important as well. The Tsk-1 model of cutaneous fibrosis, for
example, illustrates the importance of Tsk fibrillin and how it
regulates gene expression through altered interactions with
other matrix proteins.
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